Landmark Research Reveals Surprising Health Boost for Transplant Patients in Obesity-Fighting Breakthrough
As researchers at NYU Langone Health discovered, a new class of anti-obesity drugs may have an unexpected benefit for kidney transplant patients: reducing the risk of organ failure and improving survival rates. A study published in The Lancet Diabetes and Endocrinology suggests that these drugs, known as GLP-1 agonists, can also have a positive impact on patients with type 2 diabetes who have received a kidney transplant.
The study, which analyzed the medical records of 18,016 kidney transplant recipients with pretransplant diabetes, found that those prescribed GLP-1 agonists were 49% less likely to experience organ failure, also known as end-stage renal disease, and 31% less likely to die within five years of starting treatment. These medications were also found to have no increased risk of pancreas inflammation, liver problems, or thyroid cancer, which were previously concerns.
The researchers, led by Babak Orandi, MD, PhD, an associate professor in the Departments of Surgery and Medicine at NYU Grossman School of Medicine, suggest that these findings may be due to the anti-inflammatory properties of GLP-1 agonists, which can help reduce inflammation in the body. “Our study results are the strongest evidence to date that GLP-1 agonist drugs are largely safe and effective tools for addressing type 2 diabetes in kidney transplant recipients,” Orandi said in a statement.
However, the study also found that patients who took GLP-1 agonists were more likely to develop diabetic retinopathy, a serious eye condition that can lead to blindness if left untreated. Mara McAdams-DeMarco, PhD, the study’s senior investigator, an epidemiologist, and associate professor in the same departments, emphasized the importance of monitoring eye health in patients taking these medications.
These findings have significant implications for the treatment of kidney transplant patients with type 2 diabetes. Type 2 diabetes is a major cause of end-stage kidney disease, which affects nearly 250,000 Americans who require a kidney transplant. While GLP-1 agonists have been shown to be effective in reducing blood sugar levels in people with type 2 diabetes, the potential benefits in kidney transplant patients were previously unclear.
In conclusion, the study suggests that GLP-1 agonists may be a valuable treatment option for kidney transplant patients with type 2 diabetes, but further research is needed to fully understand their effects and potential risks. As researchers continue to uncover the benefits and risks of these medications, patients and healthcare providers will be able to make more informed decisions about treatment.
Original Source: https://timesofindia.indiatimes.com/life-style/health-fitness/weight-loss/new-study-finds-the-unexpected-benefits-of-anti-obesity-drugs-for-transplant-patients/articleshow/118769634.cms
Category :
Tags:
Publish Date: 2025-03-07 03:47:00
